期刊档案 · PHARMACOLOGY & PHARMACY
GaBI Journal-Generics and Biosimilars Initiative Journal
ISSN 2033-6403 · eISSN 2033-6772 · Pro Pharma Communications International
GaBI Journal-Generics and Biosimilars Initiative Journal 中科院 医学 4区（2025 年升级版），订阅期刊，收取 APC，金额未公布，2025 年发文 19 篇，ESCI、Scopus 收录。
研究范围
研究范围与定位
GaBI Journal-Generics and Biosimilars Initiative Journal 由 Pro Pharma Communications International 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Biosimilars and Bioanalytical Methods、Pharmaceutical Economics and Policy、Health Systems, Economic Evaluations, Quality of Life 等主题的论文，这 3 个主题约占 63.4%。（根据 OpenAlex 主题统计与中科院分区数据生成）
MissionThe mission of GaBI Journal is to provide an independent, high quality, authoritative, and peer reviewed platform for the publication of scientific articles concerning any aspect of the research into and development of cost-effective medicines, irrespective of their source. This Open Access journal will thus make information on pharmaceutical innovation and developments in generic and biosimilar medicines accessible to everyone, including physicians, pharmacists and nurses, patients/consumers, drug developers, third-party payers, legislators and assessors. This is achieved by: independent peer review collaboration with all relevant stakeholders (physicians/prescribers, regulatory authorities, industry, third-party payers and governments) publishing via open access channels, both in print and electronically. Scope and profileThe scope of GaBI Journal is broad and of interest and relevance to professionals active in clinical practice, pharmaceutical science and policy. Materials published in GaBI Journal include high quality research reports, literature reviews and case studies, all of which are peer reviewed. Manuscripts on all aspects of generic and biosimilar medicines, covering areas in clinical, fundamental, technical, economic and social aspects of pharmaceuticals and therapeutics are welcome. In addition, high quality work submitted in other formats, for example, scientific and evidence-based commentaries may also be considered. In all cases, the emphasis is on quality, originality and knowledge contribution to those involved in health care. All manuscripts submitted to GaBI Journal are subject to a rigorous peer review process. GaBI Journal plans to be indexed in PubMed, and that indexing will be retrospective. GaBI Journal is published quarterly. All articles are published in English. The initial circulation exceeds 5,000 copies to professionals in clinical practice and healthcare policies, pharmaceutical experts and scientists worldwide. GaBI Journal is unique as an independent, peer reviewed academic journal—it encompasses all aspects of generic and biosimilar medicines development and use, from fundamental research to clinical application and policies.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：PHARMACOLOGY & PHARMACY
主编 Robin Thorpe出版商官网
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Biosimilars and Bioanalytical MethodsImmunology and Microbiology25.8%
- Pharmaceutical Economics and PolicyEconomics, Econometrics and Finance25.2%
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance12.4%
- Pharmaceutical studies and practicesMedicine5.9%
- Biotechnology and Related FieldsMedicine4.2%
- Science, Research, and MedicineMedicine2.6%
- Biomedical Ethics and RegulationMedicine2.5%
- Safe Handling of Antineoplastic DrugsHealth Professions2.4%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
ESCIScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
PubMed出版商官网
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- CiteScore 2026-06
- 0.7LetPub ·
- SJR 2026-06
- 0.22LetPub ·
- SNIP 2026-06
- 0.33LetPub ·
- h-index
- 25OpenAlex ·
- i10-index
- 83OpenAlex ·
- 两年平均被引
- 0.63OpenAlex ·
- 自引率
- 0%LetPub ·
- Gold OA 文章占比
- 0%LetPub ·
逐年发文量 OpenAlex 统计 · 累计 535 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 1 | 0 | 25 |
| 2025 | 19 | 0 | 0 |
| 2024 | 40 | 0 | 13 |
| 2023 | 21 | 0 | 17 |
| 2022 | 21 | 1 | 17 |
| 2021 | 27 | 4 | 47 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 评审方式
- 单盲同行评审出版商官网 · 模型提取
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
订阅期刊LetPub
订阅期刊，文章需订阅或购买阅读，通常不收取版面费。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| 出版商官网 | EUR 250 | — | — |
其他费用与减免（作者指南）
- 其他费用
- 无其他费用
- 版面费
- 收取，金额见官网
- 投稿费
- EUR 250
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点4 项，摘自作者指南
- 摘要
- ≤ 250 词
- 关键词
- 3–6 个
- 正文篇幅
- ≤ 5,300 词
- 推荐审稿人
- 必须提供
接收的文章类型12 种，含篇幅限制
- brief reportCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …未说明篇幅
- commentaryCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …正文 ≤ 1,600 词
- editorialCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …未说明篇幅
- letters to the editorManuscript Submission Submit Letters to the Editor Article Processing Charges Copyright Fast Track Author Resources未说明篇幅
- meta-analysisCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …未说明篇幅
- opinionCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …未说明篇幅
- original researchCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …未说明篇幅
- original research paperCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …正文 ≤ 5,000 词
- perspective. We welcome submissions and proposals. Perspective articles are limited to 1,600 to 2,400 words and usually include one figure. There is a maximum of 20 re正文 ≤ 2,400 词
- reviewCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …未说明篇幅
- review articleCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …正文 ≤ 6,500 词
- short communicationsOriginal research, review article, meta-analysis, short communications, and letters to the Editor will be considered for publication.未说明篇幅
官网政策摘录作者资格、利益冲突、出版伦理、许可与版权、同行评审、预印本
- 作者资格 Authorship and contributorship
作者身份决定与贡献者披露是明确责任归属、为智力工作给予肯定并确保透明度的方式；多数期刊采用ICJME指南，规定作者资格应基于以下标准：对研究概念与设计、数据获取或数据分析与解释作出重要贡献；对稿件进行起草或为重要智力内容进行修改；批准拟发表的最终版本。作者必须满足全部三项标准。 模型中文摘要
Authorship decisions and contributor disclosures are explicit ways of assigning responsibility, giving credit for intellectual work and ensuring transparency. Most journals have adopted the ICJME guidelines, which state that author- ship credit should be based on the following criteria: Authors are those who made a significant contribution to (a) the study concept and design, acquisition of data, …
原文 ↗出版商官网 ·- 利益冲突 Conflict of interest disclosure
投稿时稿件必须附上利益冲突披露声明，该声明可从国际医学期刊编辑委员会（ICMJE）获取或下载；每位作者必须披露并描述与稿件中突出出现的产品的公司、与制造竞争产品的公司或与资助研究的组织之间的任何隶属关系或财务安排或关系；作者还应声明其对所有原始数据拥有完全控制权，并同意在期刊要求时允许其审查数据。 模型中文摘要
At time of submission, the manuscript must be accompanied by the Conflict of Interest Disclosure statement which is available from the International Committee of Medical Journal Editors (ICMJE), or click here to download the Conflict of Interest Disclosure statement. Each author must disclose and describe any affiliations or financial arrangements or relationships with any company whose product ap…
原文 ↗出版商官网 ·- 出版伦理
GaBI Journal遵循国际医学期刊编辑委员会（ICMJE）的标准——《向生物医学期刊投稿的统一要求：生物医学出版物的撰写与编辑》，详见www.ICMJE.org。 模型中文摘要
GaBI Journal adheres to the standard of the International Committee of Medical Journal Editors (ICMJE) – Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication, see www.ICMJE.org.
原文 ↗出版商官网 ·- 许可与版权 Copyright
发表的条件是投给GaBI Journal的稿件未曾且不会同时投给或在其他地方发表；通过提交稿件，作者同意在文章被接受发表时将其版权转让给出版商；作者须在提交稿件时签署“版权转让”表格。 模型中文摘要
It is a condition of publication that manuscripts submitted to GaBI Journal have not been and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publisher if and when the article is accepted for publication. The authors are required to sign a ‘Copyright Transfer’ form at time of manusc…
原文 ↗出版商官网 ·- 同行评审 Peer Review
所有投给GaBI Journal的稿件均须经过严格的同行评审过程；欢迎作者推荐审稿人，尽管这些建议可能会或可能不会被采用；每次投稿应附上三至四位相关研究领域专家的姓名、邮政地址和电子邮件地址。 模型中文摘要
All manuscripts submitted to GaBI Journal are subject to a rigorous peer review process. We welcome suggestions for referees from the author though these recommendations may or may not be used. Names, postal and email addresses of three to four experts in the appropriate area of research should accompany each manuscript submission. Read more →
原文 ↗出版商官网 ·- 预印本
所有文章均以电子方式在印刷前出版，并带有确定的引用行。 模型中文摘要
All articles are published electronically ahead of print with the definite citation line.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Pro Pharma Communications International
- ISSN
- 2033-6403
- 电子版 ISSN
- 2033-6772
- 官网最新一期
- Volume 15, Issue 1（2026 年）
- 官方链接
- 期刊主页 ↗OpenAlex
- 专刊 / 特刊征稿 ↗出版商官网
常见问题
关于 GaBI Journal-Generics and Biosimilars Initiative Journal 的常见问题
GaBI Journal-Generics and Biosimilars Initiative Journal 是中科院几区期刊？
2025 年升级版分区表中，GaBI Journal-Generics and Biosimilars Initiative Journal 为医学 4区，小类 药学 4 区。2026 年新锐版分区表中为医学 4区。不同版本与大小类分区不能混用。
GaBI Journal-Generics and Biosimilars Initiative Journal 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 250 词；关键词：3–6 个；正文篇幅：≤ 5,300 词；推荐审稿人：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
GaBI Journal-Generics and Biosimilars Initiative Journal 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，GaBI Journal-Generics and Biosimilars Initiative Journal 被 ESCI、Scopus 收录。期刊官网自述还被 PubMed 收录，该清单未与各数据库逐一核对。
GaBI Journal-Generics and Biosimilars Initiative Journal 是开放获取期刊吗？版面费多少？
GaBI Journal-Generics and Biosimilars Initiative Journal 为订阅期刊。收取 APC，金额未公布。
来源与更新
本页事实来自 LetPub、OpenAlex、出版商官网；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。